To several of the old school longs here... I do not share the sentiment of most here regarding the settlement. We need more details tomorrow, but it appears that the only thing INSM walks away with is the overhang of the litigation.
I do not see where INSM is getting any finances without "phase III enabling data". TRCA and DNA have wiped the floor with INSM. TRCA/DNA even Ipsen get 50% options to almost any future products for INSM. How's INSM going to get a partner or funding (short of dilution) with those terms, who's interested in part of 50%. Unless TRCA/DNA makes big investment soon when will this deal really bear fruit? and does TRCA/DNA really want it too?
Based on this arrangement, I think INSM would have been better off letting the verdict ride and taking their chances. What really is the difference? (unless there's something undisclosed ) INSM has effectively enjoined themselves from the short stature market / the only current revenue stream we had. And we did so voluntarily? Allan always had a penchant to go it alone but now at what cost... The Boulder plant really was a stupid investment now (rstor was right based on today's events, I've reversed on that one...). INSM probably has enough product produced for years on years worth of clinical trials now... Based on this agreement, is there even room for INSM to develop non-infringing processes and compete, it doesn't seem so...
I hate to say it, but unless there's a hidden gem in there somewhere, we are going to get killed tomorrow....
News 
Market Data 
Discover 
